top of page
GPCR News
Blog: Blog2
Search
Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...
Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
November 2022 "Recently determined structures of class C G protein-coupled receptors (GPCRs) revealed the location of allosteric binding...
Conservation of Allosteric Ligand Binding Sites in G-Protein Coupled Receptors
November 2022 "Despite the growing number of G protein-coupled receptor (GPCR) structures, only 39 structures have been cocrystallized...
Dimerization of β2-adrenergic receptor is responsible for the constitutive activity subjected to inv
November 2022 "Dimerization of beta 2-adrenergic receptor (β2-AR) has been observed across various physiologies. However, the function of...
Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine..
October 2022 Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for...
Structural basis of adhesion GPCR GPR110 activation by stalk peptide and G-proteins coupling
October 2022 "Adhesion G protein-coupled receptors (aGPCRs) are keys of many physiological events and attractive targets for various...
GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for...
October 2022 GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor...
Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of...
October 2022 Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor...
Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi "San...
Amgen to Acquire Chemocentryx for $4 Billion in Cash
August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc.,...
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders "Geneva,...
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring...
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS...
Trevena Reports Second Quarter 2022 Results and Provides Business Update
August 2022 "CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the...
G.CLIPS biotech is 2 years old this month!
July 2022 "G.CLIPS biotech is 2 years old today🎂. When I came this morning to work this is how I found my desk. So very grateful to the...
X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming its pipeline. The Boston biotech...
Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross Bathgate Read more at...
Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...
July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022...
bottom of page